Vanguard Capital Management
HBIO icon

Vanguard Capital Management’s Harvard Bioscience HBIO Stock Holding History

Vanguard Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
169,625
+6,312
+4% +$37.8K ﹤0.01% 3588
2026
Q1 		$795K Buy
+163,313
New +$913K ﹤0.01% 3595

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Vanguard Capital Management's HBIO Position: Q2 2026 in Review

Vanguard Capital Management increased its Harvard Bioscience (HBIO) stake by 3.9% in Q2 2026, buying an estimated $37.8K and bringing the position to 169,625 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3588.

Vanguard Capital Management first reported a position in HBIO in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Vanguard Capital Management held 169,625 shares of Harvard Bioscience worth $1.04M as of Q2 2026.
  • Vanguard Capital Management bought 6,312 Harvard Bioscience shares in Q2 2026, an estimated $37.8K.
  • Harvard Bioscience made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3588 holding.
  • Vanguard Capital Management first reported a position in Harvard Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.